NCI High Priority Clinical Trial
SWOG-9321, INT-0141, CLB-9312 Phase III Randomized
Study of L-PAM/TBI With PBSC Rescue vs VBMCP (VCR/BCNU/L-PAM/ CTX/PRED)
Following Standard Induction for Previously Untreated Symptomatic Multiple
Myeloma, With Further Randomization for Major Responders to IFN-A vs Observation
(summary last modified: 12/97).
Chairperson: Bart Barlogie. Lead organization: Southwest Oncology Group.
Age range: not over 70.
Phase III
CAN-NCIC-MY7, NCI-V95-0713 Phase III Randomized
Study of L-PAM Plus DM vs PRED as Induction Therapy for Symptomatic Myeloma
and of DM vs No Additional Treatment as Maintenance Therapy for Stabilized
Disease (summary last modified: 10/96).
Chairperson: Chaim Shustik. Lead organization: NCIC-Clinical Trials
Group. Age range: 18 and over.
MRC-LEUK-MYEL-VII, EU-94030 Phase III Randomized
Study of Standard Therapy With ABCM (DOX/BCNU/CTX/L-PAM) vs Intensive Therapy
With C-VAMP (CTX/ VCR/DOX/MePRDL) Followed by High-Dose L-PAM (With or
Without TBI) With Hematopoietic Rescue, Both With IFN-A Maintenance, for
Previously Untreated Myeloma (summary last modified: 02/95).
Chairperson: J. A. Child. Lead organization: Medical Research Council’s
Working Party on Leukemia in Adults and Children. Age range: under 65.
MRC-LEUK-MYEL-VIII, EU-94031 Phase III
Randomized Study of ABCM (DOX/BCNU/CTX/L-PAM) vs ABCM Followed by Oral
CTX/PRED for Induction of First Plateau Phase in Elderly Patients With
Multiple Myeloma (summary last modified: 09/95).
Chairperson: Ian C.M. MacLennan. Lead organization: Medical Research
Council’s Working Party on Leukemia in Adults and Children. Age range:
under 75.
E-5A93 Phase III Randomized Study of VBMCP
(VCR/BCNU/L-PAM/CTX/PRED) Alone vs VBMCP Alternating First With High-Dose
CTX, Then With IFN-A in Patients With Previously Untreated Multiple Myeloma
(summary last modified: 18 and over).
Chairperson: Robert A. Kyle. Lead organization: Eastern Cooperative
Oncology Group. Age range: 18 and over.
E-1A95, CAN-NCIC-J1A95, CAN- NCIC-MY8, SWOG-S1A95
Phase III Randomized Study of Vincristine/ Doxorubicin/Dexamethasone (VAD)
With vs Without PSC 833 in Relapsed/Refractory Multiple Myeloma (summary
last modified: 03/98).
Chairperson: William R. Friedenberg. Lead organization: Eastern Cooperative
Oncology Group. Age range: 18 and over.
Phase II
MAYO-928003, NCI-V95-0613 Phase II Study of
High-Dose L-PAM Plus TBI With PBSC Rescue for Multiple Myeloma in First
Relapse (summary last modified: 06/95).
Chairperson: Morie Abraham Gertz. Lead organization: Mayo Clinical Cancer
Center. Age range: 18-65.
FHCRC-1204.00, NCI-H97-0007 Phase II Study
of Busulfan, Melphalan, and Thiotepa Followed by Autologous or Syngeneic
Marrow or Peripheral Blood Stem Cell Transplantation in Patients With Multiple
Myeloma (summary last modified: 02/98).
Chairperson: William I. Bensinger. Lead organization: Fred Hutchinson
Cancer Research Center. Age range: 70 and under.
WSU-C-1257, NCI-T95-0062D, WSU-D-1257 Phase
II Study of Bryostatin 1 in Relapsed Multiple Myeloma (summary last modified:
06/97)
Chairperson: Mary L. Varterasian. Lead organization: Barbara Ann Karmanos
Cancer Institute. Age range: 18 and over.
MAYO-968001, NCI-V96-1079 Phase II Study
of High-Dose Dexamethasone for Primary Systemic Amyloidosis (summary last
modified: 12/96).
Chairperson: Morie Abraham Gertz. Lead organization: Mayo Clinical Cancer
Center. Age range: 18 and over.
UARK-94016, NCI-T94-0176O Phase II Pilot
Study of Suramin for Refractory or Relapsed Multiple Myeloma and Castleman’s
Disease (summary last modified: 01/97).
Chairperson: Madhav Dhodapkar. Lead organization: University of Arkansas
for Medical Sciences - Little Rock. Age range: over 18.
SWOG-S9628, SWOG-9628 Phase II Study of
Dexamethasone/Interferon alfa for Primary Systemic Amyloidosis (summary
last modified: 03/98).
Chairperson: Madhav Dhodapkar. Lead organization: Southwest Oncology
Group. Age range: adult.
MAYO-958002, NCI-V96-0837 Phase II Study
of TBI Plus High-Dose L-PAM With PBSC Rescue for Primary Systemic Amyloidosis
(summary last modified: 06/96).
Chairperson: Morie Abraham Gertz. Lead organization: Mayo Clinical Cancer
Center. Age range: 18-70.
MCW-96110, NCI-V97-1368, MCW- HRRC-29196
Phase II Study of Myeloablative Therapy With Autologous Hematopoietic Stem
Cell Transplantation in Patients With Multiple Myeloma or Other B-Cell
Malignancies (summary last modified: 02/98).
Chairperson: David H. Vesole. Lead organization: Medical College of
Wisconsin. Age range: 18 and over.
WSU-D-701-87, NCI-V94-0364 Phase II Study
of Bone Marrow Transplantation for Refractory or High-Risk Non-Hodgkin’s
Lymphoma, Hodgkin’s Disease, and Multiple Myeloma (summary last modified:
10/97).
Chairperson: Chatchada Karanes. Lead organization: Barbara Ann Karmanos
Cancer Institute. Age range: not over 60.
FHCRC-1272.00, NCI-H98-0009 Phase II Study
of Total Marrow Irradiation, Busulfan, and Interfer on Alfa Followed by
Allogeneic Peripheral Blood Stem Cell or Marrow Transplantation in Patients
With Advanced Multiple Myeloma (summary last modified: 03/98).
Chairperson: William I. Bensinger. Lead organization: Fred Hutchinson
Cancer Research Center. Age range: 18 to 65.
PCI-9317, NCI-V93-0287 Phase II Study of
High-Dose Chemotherapy and Autologous Stem Cell Support Followed by Low-Dose
IL-2 in Patients With Relapsed or Resistant Multiple Myeloma (summary last
modified: 12/93.
Chairperson: Witold B. Rybka. Lead organization: University of Pittsburgh
Cancer Institute. Age range: over 18 to under 65.
CHNMC-94087-94-11-1, NCI-V94- 0590 Phase
II Pilot Study of Sequential High-Dose L-PAM and BU/CTX Followed by PBSC
Rescue for Multiple Myeloma (summary last modified: 03/95.
Chairperson: George Somlo. Lead organization: Beckman Research Institute
of the City of Hope. Age range: 65 and under.
NCI-97-C-0033, NCI-T94-0094N, CRB-9409
Phase II Evaluation of Cellular and Humoral Immunity Against a Tumor-Derived
Immunoglobulin Idiotype in Multiple Myeloma Patients Undergoing Autologous
PBMC Transplantation after Idiotype Vaccination (summary last modified:
05/97).
Chairperson: Larry W. Kwak. Lead organization: Division of Clinical
Sciences. Age range: any age.
TUHSC-2797, NCI-V96-0951 Phase II Study
of High-Dose Melphalan Followed by Autologous Peripheral Blood Stem Cell
Transplantation in Primary Amyloidosis or Amyloidosis Secondary to Multiple
Myeloma (summary last modified 01/98).
Chairperson: Kenneth F. Mangan. Lead organization: Temple University
Cancer Center. Age range: 16 to 65.
SWOG-S9612, SWOG-9612 Phase II Study of
Oral VP-16 and Intravenous BCNU in Refractory Multiple Myeloma (summary
last modified: 05/96).
Chairperson: Charles A. Coltman, Jr. Lead organization: Southwest Oncology
Group. Age range: no age specified.
E-2A97 Phase II Study of Docetaxel in Patients
With Relapsed or Refractory Multiple Myeloma (summary last modified: 04/98).
Chairperson: William R. Friedenberg. Lead organization: Eastern Cooperative
Oncology Group. Age range: 18 and over.
NCI-97-C-0030, NCI-T94-0085N, CRB-9407
Phase II Study of Active Immunization of Related Bone Marrow Transplant
Donors Against Purified Myeloma Protein from the Recipient Undergoing Allogeneic
Bone Marrow Transplantation (summary last modified: 02/98).
Chairperson: Larry W. Kwak. Lead organization: Division of Clinical
Sciences. Age range: under 60.
E-1A97 Phase II Study of Salvage Cellular
Immunotherapy With Donor Lymphocyte Infusions in Patients With Recurrent
Multiple Myeloma After Allogeneic Bone Marrow Transplantation from an HLA-Matched
Sibling Donor (summary last modified: 04/98).
Chairperson: Neal Flomenberg. Lead organization: Eastern Cooperative
Oncology Group. Age range: 18 and over.
E-1A96 Phase II Study of Interleukin-12
(IL-12) in Patients With Plateau Phase Multiple Myeloma (summary last modified:
04/98).
Chairperson: Martha Q. Lacy. Lead organization: Eastern Cooperative
Oncology Group. Age range: 18 and over.
Phase I/Pilot Studies
FHCRC-1104.00, NCI-H96-0924 Phase I Study
of Posttransplant Immunization With Autologous Myeloma Idiotype (Id) Conjugated
to Keyhole Limpet Hemocyanin (KLH) and Administered With GM-CSF Following
Autologous or Allogeneic Marrow or Stem Cell Transplantation in Myeloma
Patients (summary last modified: 02/98).
Chairperson: David G. Maloney. Lead organization: Fred Hutchinson Cancer
Research Center. Age range: 18 to 65.
MDA-DM-91104, NCI-G96-0992 Phase I Trial
of 166 Holmium- DOTMP With Autologous Bone Marrow Transplantation for Advanced
Multiple Myeloma (summary last modified: 06/97).
Chairperson: Richard E. Champlin. Lead organization: University of Texas
- M.D. Anderson Cancer Center. Age range: less than 60.
UTENNM-BCG-5889, NCI-V97-1263 Pilot Study
of Interferon Alfa-2b (Intron A) Maintenance in Patients With Advanced
Multiple Myeloma Who Have Used High Dose Melphalan (L-PAM) as Myeloablative
Chemotherapy (summary last modified: 02/98).
Chairperson: C. Michael Jones. Lead organization: University of Tennessee,
Memphis. Age range: 19 to 64.
MDA-DM-94132, NCI-G96-1006 Phase I/II Randomized
Study of Cyclosporine Induced Autologous Graft Versus Host Disease (GVHD)
Following Peripheral Blood Stem Cell Transplantation in Multiple Myeloma
(summary last modified: 06/97).
Chairperson: Sergio Giralt. Lead organization: University of Texas -
M.D. Anderson Cancer Center. Age range: 15 to 60.
STLMC-BRM-9501, NCI-V95-0735 Phase I Study
of Cytotoxic T-Cell Infusion With PBSC Transplantation for Acute Leukemia,
Hodgkin’s Disease, non-Hodgkin’s Lymphoma, and Multiple Myeloma (summary
last modified: 01/98).
Chairperson: Lawrence George Lum. Lead organization: St. Luke’s Medical
Center. Age range: 13 and over.
FHCRC-976.02, NCI-H95-0703, FHCRC-976.01
Phase I Pilot Study of Interleukin-2-Activated Peripheral Blood Stem Cell
Rescue Following Myeloablative Chemotherapy and of Post-Transplant Interleukin-2
for Stage IV Breast Cancer and Advanced Lymphoma, Multiple Myeloma, and
Ovarian Cancer (summary last modified: 02/98).
Chairperson: Leona Holmberg. Lead organization: Fred Hutchinson Cancer
Research Center. Age range: 18 to 55.
Support
URCC-U10994, NCI-P96-0073, NCI-C95-0001, URCC-10994P(M)
Randomized Study of Trimethoprim-Sulfamethoxazole vs Cipro-floxacin or
Ofloxacin vs No Prophylaxis for the Prevention of Early Infection in Multiple
Myeloma Patients (summary last modified: 12/97).
Chairperson: John M. Bennett. Lead organization: University of Rochester
Cancer Center. Age range: any age.
Legend for Abbreviations:
CAN-NCIC = National Cancer Institute of Canada
CHNMC = City of Hope National Medical Center
E = Eastern Cooperative Oncology Group
EU = NCI-Liaison Office- Approved Eutopean Voluntary Protocol
FHCRC = Fred Hutchinson Cancer Research Center
MAYO = Mayo Clinic
MCW = Medical College of Wisconsin
MDA = M. D. Anderson Cancer Center
MRC = Medical Research Council
PCI = Pittsburgh Cancer Institute
STLMC = St. Luke’s Medical Center
SWOG = Southwest Oncology Group
TUHSC = Temple University Health Sciences Center
UARK = University of Arkansas
URCC = University of Rochester Cancer Center
UTENNM = University of Tennessee College of Medicine
WSU = Wayne State University